Alvogen Recalls Nifedipine Extended-Release Tablets Due to Sorafenib Cross-Contamination
Alvogen, Inc. is recalling Nifedipine Extended-Release Tablets, 30 mg, due to cross-contamination with sorafenib powder found in the manufacturing facility's inlet air duct.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as unlikely to cause adverse health consequences. The rubric maps Class III recalls to scores of 1 or 2; a score of 2 is appropriate for a cross-contamination issue involving a potent pharmaceutical agent, even if the immediate risk is low.
Plain-English summary
Alvogen, Inc. is recalling Nifedipine Extended-Release Tablets, 30 mg, 100-count bottles (NDC 47781-368-01). The recall is being conducted because residual powder identified as sorafenib was found in the inlet air duct of the manufacturing facility, indicating cross-contamination with another product.
The affected lots include BXH1P22, BXH1P21A, BXH1P21, BXH1P31, and BXH1P21B with expiration dates of 11/2017; BXH6EL1, BXH66A1, BXH6EN1, BXH6EP1, and BXH6ER1 with expiration dates of 06/2018; and BXH81K1A and BXHBJD1A with expiration dates of 10/2018. The products were distributed nationwide.
Consumers and healthcare providers should stop using the recalled products and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
The recalled product
- Product
- Nifedipine Extended-Release Tablets, 30 mg, 100-count bottles, Rx Only, Manufactured for Alvogen Inc. Pine Brook, NJ 07058 USA, NDC 47781-368-01.
- Manufacturer
- Alvogen, Inc
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Lot #: BXH1P22
- BXH1P21A
- BXH1P21
- BXH1P31
- BXH1P21B
- Exp. 11/2017
- BXH6EL1
- BXH66A1
- BXH6EN1
- BXH6EP1
- BXH6ER1
- Exp. 06/2018
- BXH81K1A
- BXHBJD1A
- Exp. 10/2018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 9 recalled by Alvogen, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 9 products in this recall →Related recalls
Same manufacturer · Alvogen, Inc
See all →- ModerateCarotid anesthesia kits recalled over recalled B. Braun administration sets inside
FDA (Drugs) · 2026-01-21
- SevereFentanyl Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2025-02-26
- ModeratePrescription Levothyroxine Sodium Tablets Recalled Due to Sub-Potency
FDA (Drugs) · 2023-03-08
- SevereAlvogen Buprenorphine and Naloxone Sublingual Film recalled for subpotent active ingredients
FDA (Drugs) · 2021-07-14
- ModerateAlvogen Recalls Nitrofurantoin Capsules Due to Failed Dissolution Specifications
FDA (Drugs) · 2019-08-21
Same hazard · cross contamination
See all →- CriticalCetirizine Hydrochloride Tablets Recalled Due to Cross Contamination with Ranitidine
FDA (Drugs) · 2026-07-29
- ModeratePrimidone tablets recalled over potential acemetacin cross-contamination at API manufacturer
FDA (Drugs) · 2026-06-17
- HighFly By Jing creamy sesame noodles may contain undeclared peanut
FDA (Food) · 2026-06-03
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27